An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Parvataneni, Swetha; Ramachandran, Rajarajeshwari; Then, Eric O.; Grantham, Tyler; Gaduputi, Vinaya

doi:10.1155/2021/6306149

Cited by 3 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the temporal association of liraglutide initiation and liver injury, DILI from glucagon-like peptide 1 agonists is rare (likelihood score E). [10][11][12][13] In large clinical trials, there was no significant difference in transaminase elevation between liraglutide and placebo. 10 Over the last decade, only single case reports of glucagon-like peptide 1 agonist hepatotoxicity exist.…”

Section: Discussionmentioning

confidence: 99%

“…10 Over the last decade, only single case reports of glucagon-like peptide 1 agonist hepatotoxicity exist. [10][11][12][13] One case reported liraglutideassociated autoimmune hepatitis that did not resolve with discontinuation of liraglutide and required long-term corticosteroids. 13 Otherwise, there are 2 published cases of liraglutideassociated DILI that demonstrated hepatocellular injury and resolved after discontinuing the drug.…”

Section: Discussionmentioning

confidence: 99%

“…13 Otherwise, there are 2 published cases of liraglutide-associated DILI that demonstrated hepatocellular injury and resolved after discontinuing the drug. 11,12 The home hepatotoxic medications with likelihood score A must be taken in high doses to cause DILI, and he was not taking such doses (Table 1). Metformin (likelihood B) can causes minor transaminase elevation but rarely causes clinically apparent ALI.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine

Power,

Barritt

2024

ACG Case Rep J

View full text Add to dashboard Cite

Greater celandine (Chelidonium majus) leaf extracts have been used for centuries as a natural remedy for various gastrointestinal symptoms. Greater celandine is associated with several case reports of hepatotoxicity, mainly from Europe. No cases from the United States have been identified. We present a case of acute hepatitis from greater celandine in the United States in a 72-year-old man taking this herbal supplement for nausea. In patients presenting with acute liver injury, gastroenterologists should be aware of this herb and reminded to assess for herbal and dietary supplement hepatotoxicity, especially in those remedies used to treat common gastrointestinal symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine

Power,

Barritt

2024

ACG Case Rep J

View full text Add to dashboard Cite

show abstract

“…Results that were considered irrelevant, redundant, duplicate, non-English, or related to bench research were excluded by 2 physicians. Eventually, we found only 4 articles where DILI was described in association with liraglutide use, dating from 2014 to 2021 [16][17][18][19]. All 4 articles were case reports based on individual patient experiences (level of clinical evidence: IV).…”

Section: Discussionmentioning

confidence: 99%

“…Hepatotoxicity improved after liraglutide cessation [18]. Parvataneni et al reported a case of liraglutide-induced DILI in a diabetic female [19]. There was complete recovery with the discontinuation of the medication [19].…”

Section: Discussionmentioning

confidence: 99%

Drug-induced liver injury associated with liraglutide use: a case-based review of detection, severity, causality assessment, and clinical outcomes

2023

J Clin Transl Res

View full text Add to dashboard Cite

Background and Aim: Drug-induced liver injury (DILI) remains the most important etiology of acute liver failure in the United States. It often presents a diagnostic conundrum due to the lack of a specific biomarker or diagnostic modality. Liraglutide, a glucagon-like peptide-1 agonist, has recently gained clinical importance for its anti-obesity and anti-diabetic effects. While a constellation of adverse events has been reported, the published data on its hepatotoxic potential remains limited. We hereby delineate a rare case of liraglutide-associated DILI. Furthermore, a systematic review of MEDLINE, Google Scholar, Scopus, and Cochrane databases was conducted on DILI following liraglutide therapy. Specific terminologies were used to identify relevant English-language articles. The latest search date was December 20, 2022. Our search identified a total of 4 case reports (level of clinical evidence: IV). We discuss the limited available data on detection, severity, causality assessment, and clinical outcomes in patients with liraglutide-induced DILI. Relevance for Patients: DILI rarely occurs in patients undergoing liraglutide therapy. Clinicians and hepatologists can play a key role by promptly recognizing and stopping the offending agent. Therefore, intensive pharmacovigilance is imperative for ensuring patient safety and clinical effectiveness. Patients on liraglutide may be considered for baseline testing and periodic liver function monitoring.

show abstract

Liraglutide and Liver Injury: Rare Case Report with Literature Review

Salehi,

Hasanzarrini,

Salehi

et al. 2024

EMIDDT

View full text Add to dashboard Cite

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus (T2DM). So far, few severe side effects have been reported for it. Case Presentation: A 41-year-old woman was admitted to the Emergency Room with diffuse abdominal pain. The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan. Her liver functional test (LFT) was consistent with hepatocellular injury; however, laboratory tests and abdominal ultrasound were used to rule out autoimmune hepatitis. Due to concerns for drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl cysteine was prescribed. On the fifth day of hospitalization, the patient's symptoms resolved and his LFT started to decrease on the sixth day after 2 months, the patient's liver enzyme levels returned to normal. Conclusion: Liraglutide is one of the most important drugs in the treatment of T2DM.The most common side effects of this drug are constipation, nausea, vomiting, diarrhea, indigestion, and loss of appetite. In rare cases, symptoms of thyroid cancer, pancreatitis, and hypoglycemia have been reported, however, DILL is one of the extremely rare side effect of Liraglutide. It is important to increase the awareness of physicians about the liver injury of Liraglutide.

show abstract

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Abstract: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.

Cited by 3 publications

References 15 publications

A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine

A Yellow Flower With Jaundice Power: Liver Injury Attributed to Greater Celandine

Drug-induced liver injury associated with liraglutide use: a case-based review of detection, severity, causality assessment, and clinical outcomes

Liraglutide and Liver Injury: Rare Case Report with Literature Review

Contact Info

Product

Resources

About